Dostarlimab

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer.

[5][6] Additional side effects reported in the European Union include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).

[14] In the European Union, dostarlimab is indicated as monotherapy for the treatment of adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-based regimen such as cisplatin, carboplatin or oxaliplatin.

Traditional surgery patients often experience life-long impacts, such as bowel, urinary and sexual dysfunction, as well as secondary cancers and infertility.

[24][25] Serious adverse reactions in >2% of patients included sepsis, acute kidney injury, urinary tract infection, abdominal pain, and fever (pyrexia).

[5][6] Immune-mediated adverse reactions can occur including pneumonitis, colitis, hepatitis, endocrine disease (endocrinopathies), and nephritis.

[5][6] The most common side effects reported while taking this medication during a trial were dyspnea, asthenia, fatigue, and nausea.

[26] Symptoms of overdose are similar to the side effect profile of the medication, so it could involve significant immune-mediated reactions.

[29] Therefore, blocking the binding of PD-1 to these ligands can allow T-cells to function normally and prevent tumor cells from bypassing immune surveillance.

[5] In the Garnet Trial, dostarlimab achieved favorable results in decreasing the size of the tumor in those with endometrial cancer.

[31][35] In 2020, the Garnet study announced that dostarlimab had promising potential to treat a specific subset of individuals with recurrent or advanced endometrial cancer.

[36] In April 2021, the US Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli, GSK).

[37] In 2022, an early clinical study of dostarlimab reported a 100% remission rate in 14 patients with rectal cancer who had mismatch repair deficiency, a type of genetic mutation that only affects 5-10% of cases.

[38][39][40] In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.